There are currently 834 clinical trials in Indianapolis, Indiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Indiana University, Indiana University Melvin and Bren Simon Cancer Center, Riley Hospital for Children and Indiana University Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients
Recruiting
This is a single-center, proof-of-concept pilot study which uses a cross-over design to compare two dietary interventions/treatments: Western Diet (WD) vs Mediterranean (MD) and impact on quality-of-life parameters in AIH. Participants will receive both treatments through two phases and will be divided into two groups.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/19/2024
Locations: IU Health University Hosptial, Indianapolis, Indiana
Conditions: Autoimmune Hepatitis
Prevalence of Hemorrhagic Myocardial Infarction in the United States
Recruiting
Registry analysis for prevalence of hemorrhagic myocardial infarction in the United States
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2024
Locations: Krannert Cardiovascular Research Center, Indianapolis, Indiana
Conditions: Acute Myocardial Infarction
STAT: Standard Therapy Plus Active Therapy
Recruiting
The objective of the study is to assess the efficacy of STAT, an activity-based therapy protocol compared to standard therapy (ST) to improve functional outcome and reduce disability in patients recovering from burn injury. This randomized multi-center trial is designed with two parallel treatment groups: STAT and ST. Efficacy of the STAT protocol will be determined through comparison to the ST only group. It will be conducted at seven burn centers.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/31/2024
Locations: Health and Hospital Corporation dba Eskenazi Health, Indianapolis, Indiana
Conditions: Burn Injury, Physical Injury, Thermal Burn
Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants
Recruiting
The main purpose of this study is to measure the efficacy of farudodstat compared to placebo at Week 12 from the treatment start, in adult participants with Alopecia Areata (AA) with 30% or greater scalp hair loss.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: 1 Site, Indianapolis, Indiana
Conditions: Alopecia Areata
Pediatric Vasculitis Initiative
Recruiting
Childhood chronic vasculitis describes a group of rare life-threatening diseases that have in common inflammation of blood vessels in vital organs such as kidneys, lungs and brain. Most knowledge about them comes from adult patients. Severe disease requires aggressive life-saving treatments with steroids and some cancer drugs which can themselves cause damage, and increase risks of cancer and severe infections. Conversely, milder disease can be treated with less toxic drugs. Different classifica... Read More
Gender:
ALL
Ages:
20 years and below
Trial Updated:
11/27/2023
Locations: Riley Hospital for Children, Indianapolis, Indiana
Conditions: Wegeners Granulomatosis (Granulomatosis With Polyangiitis), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis, Primary CNS Vasculitis, Unclassified Vasculitis, Eosinophilic Granulomatosis With Polyangiitis
Exercise Intervention in Adolescent and Young Adult Cancer Survivors
Recruiting
Adolescent and young adult (AYA) survivors of cancer face a future of persistent medical issues across a wide spectrum of diseases One study examining health data from this cohort (ages 15-29) reported significantly higher rates of smoking, obesity, cardiovascular disease, hypertension, asthma, and poorer mental health among the cancer survivors when compared to healthy controls. Prescribed exercise has broad and far-reaching beneficial physiological effects that cut across multiple body systems... Read More
Gender:
ALL
Ages:
Between 15 years and 39 years
Trial Updated:
11/27/2023
Locations: Riley Hospital for Children - Indiana University, Indianapolis, Indiana +1 locations
Conditions: Long-term Effects Secondary to Cancer Therapy in Adults, Pediatric Cancer
The KinematX Midcarpal Total Wrist Arthroplasty Registry
Recruiting
The goal of this observational study is to learn about functional and patient reported outcomes in patient undergoing total wrist replacement with the KinematX total wrist replacement study. The main questions it aims to answer are: * What is the range of motion (flexion, extension, radial, ulnar, grip and pinch strength) at 3-, 6-, and 12-months after surgery and yearly up to 10 years among patients having total wrist replacement with the KinematX implant. * What are the patient reported outc... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
11/13/2023
Locations: Franciscan Health, Indianapolis, Indiana
Conditions: Scapholunate Advanced Collapse (SLAC), Scapholunate Crystalline Advanced Collapse (SCAC), Scaphoid, Trapezium, and Trapezoid Advanced Collapse (STTAC), Carpal Tunnel Syndrome (CTS), Kienbock's Disease of Adults, Radial Malunion, Ulnar Translocation, Post Traumatic Arthritis, Inflammatory Arthritis, Osteoarthritis, Scaphoid Non-union Advanced Collapse (SNAC)
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter, study to evaluate the efficacy, safety, and pharmacokinetics (PK) of budesonide extended-release tablets for the induction of remission in pediatric subjects, with active, mild to moderate ulcerative colitis (UC). Subjects will be permitted to continue taking background oral or rectal 5-aminosalicylate (5-ASA) products.
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
10/05/2023
Locations: Bausch Health Site 003, Indianapolis, Indiana
Conditions: Ulcerative Colitis
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Recruiting
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/07/2023
Locations: Indiana University Health, Indianapolis, Indiana
Conditions: NASH - Nonalcoholic Steatohepatitis
Spironolactone in CKD Enabled by Chlorthalidone: PILOT
Recruiting
Highly prevalent among patients with chronic kidney disease (CKD) and poorly controlled blood pressure (BP), is a modifiable risk factor to abrogate both kidney failure progression and cardiovascular (CV) disease. Spironolactone (SPL), a mineralocorticoid receptor antagonist, is widely used to treat resistant hypertension, however one of the most common side effects is an increase of serum potassium (K). This side effect occurs frequently in those who suffer from CKD. Alternatively, chlorthalido... Read More
Gender:
ALL
Ages:
Between 19 years and 110 years
Trial Updated:
08/11/2023
Locations: Richard L Roudebush VA Medical Center, Indianapolis, Indiana
Conditions: Renal Insufficiency, Chronic Hypertension
Terumo Aortic Global Endovascular Registry
Recruiting
Multi-arm, multi-center, open label, prospective observational registry designed to obtain safety and performance data on the use of CE marked and custom Terumo Aortic endovascular grafts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2023
Locations: Ascension St. Vincent Heart Center, Indianapolis, Indiana
Conditions: Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2023
Locations: Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Conditions: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma